BC Innovations | Sep 15, 2016
Targets & Mechanisms

KOR-recting MS

Although the failed Phase II multiple sclerosis trial of Biogen Inc. 's anti-LINGO mAb in June dealt a blow to myelin repair, a slew of compounds acting by different mechanisms lies behind it in clinical...
BC Innovations | Mar 17, 2011
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Nerve damage Myosin, heavy chain 10 non-muscle (MYH10; NMHCII) Cell culture studies suggest that inhibiting MYH10 could help treat nerve damage....
BC Innovations | Sep 16, 2010
Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Culture of human pluripotent stem (hPS) cells in non-muscle myosin II (MYH10; NMHCII)-depleted conditions to improve viability and increase available cells for clinical applications...
Items per page:
1 - 3 of 3